{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:31:11Z","timestamp":1786570271655,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,12]]},"DOI":"10.7759\/cureus.114435","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:05:38Z","timestamp":1786568738000},"source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide)\/GLP-1 Receptor Agonists for Antipsychotic-Induced Weight Gain: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Agnieszka","family":"Buczkowska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Glinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Danieluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Adamaszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urszula","family":"Kacprzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Dolega-Mostowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Stochaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalina","family":"Flejszman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Wojcik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sochowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068652","article-title":"Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry)","volume":"13","author":"Sass MR","year":"2023","unstructured":"Sass MR, Danielsen AA, K\u00f6hler-Forsberg O, et al.. Effect of the GLP-1 receptor agonist semaglutide on metabolic disturbances in clozapine-treated or olanzapine-treated patients with a schizophrenia spectrum disorder: study protocol of a placebo-controlled, randomised clinical trial (SemaPsychiatry). BMJ Open. 2023, 13:e068652. 10.1136\/bmjopen-2022-068652","journal-title":"BMJ Open"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111336","article-title":"Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain","volume":"8","author":"Grajales D","year":"2019","unstructured":"Grajales D, Ferreira V, Valverde \u00c1M. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells. 2019, 8:1336. 10.3390\/cells8111336","journal-title":"Cells"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/07067437251386626","article-title":"GLP-1 receptor agonists as a novel solution for antipsychotic-induced weight gain in severe and persistent mental illness","volume":"71","author":"Jacobson S","year":"2026","unstructured":"Jacobson S, Margolese N, Margolese HC. GLP-1 receptor agonists as a novel solution for antipsychotic-induced weight gain in severe and persistent mental illness. Can J Psychiatry. 2026, 71:413-9. 10.1177\/07067437251386626","journal-title":"Can J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11030669","article-title":"Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials","volume":"11","author":"Patoulias D","year":"2023","unstructured":"Patoulias D, Michailidis T, Dimosiari A, Fragakis N, Tse G, Rizzo M. Effect of glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors among obese\/overweight individuals treated with antipsychotic drug classes: an updated systematic review and meta-analysis of randomized controlled trials. Biomedicines. 2023, 11:669. 10.3390\/biomedicines11030669","journal-title":"Biomedicines"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.625935","article-title":"Clinical, biochemical and genetic variables associated with metabolic syndrome in patients with schizophrenia spectrum disorders using second-generation antipsychotics: a systematic review","volume":"12","author":"Sneller MH","year":"2021","unstructured":"Sneller MH, de Boer N, Everaars S, Schuurmans M, Guloksuz S, Cahn W, Luykx JJ. Clinical, biochemical and genetic variables associated with metabolic syndrome in patients with schizophrenia spectrum disorders using second-generation antipsychotics: a systematic review. Front Psychiatry. 2021, 12:625935. 10.3389\/fpsyt.2021.625935","journal-title":"Front Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/obesities5040072","article-title":"Impacts of glucagon-like peptide-1 receptor-agonist (GLP-1 RA) treatment for metabolic disturbances and weight gain in patients on clozapine\/olanzapine: a systematic review","volume":"5","author":"Varshney K","year":"2025","unstructured":"Varshney K, Panda S, Fernando H, Sava S, Khan T. Impacts of glucagon-like peptide-1 receptor-agonist (GLP-1 RA) treatment for metabolic disturbances and weight gain in patients on clozapine\/olanzapine: a systematic review. Obesities. 2025, 5:72. 10.3390\/obesities5040072","journal-title":"Obesities"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2023.12054","article-title":"Therapeutic management of atypical antipsychotic\u2011related metabolic dysfunctions using GLP\u20111 receptor agonists: a systematic review","volume":"26","author":"Vasiliu O","year":"2023","unstructured":"Vasiliu O. Therapeutic management of atypical antipsychotic\u2011related metabolic dysfunctions using GLP\u20111 receptor agonists: a systematic review. Exp Ther Med. 2023, 26:355. 10.3892\/etm.2023.12054","journal-title":"Exp Ther Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ph14030238","article-title":"Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences","volume":"14","author":"Carli M","year":"2021","unstructured":"Carli M, Kolachalam S, Longoni B, et al.. Atypical antipsychotics and metabolic syndrome: from molecular mechanisms to clinical differences. Pharmaceuticals. 2021, 14:238. 10.3390\/ph14030238","journal-title":"Pharmaceuticals"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.12775\/JEHS.2024.75.56672","article-title":"Glucagon-like peptide-1 receptor agonists as a therapeutic option for antipsychotic-induced obesity: a review of current evidence","volume":"75","author":"Gnia\u017a N","year":"2024","unstructured":"Gnia\u017a N, G\u00f3rska A, Grela W, et al.. Glucagon-like peptide-1 receptor agonists as a therapeutic option for antipsychotic-induced obesity: a review of current evidence. J Educ Health Sport. 2024, 75:56672. 10.12775\/JEHS.2024.75.56672","journal-title":"J Educ Health Sport"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12775\/JEHS.2026.87.67433","article-title":"GLP-1 receptor agonists: a new hope in the global fight against obesity: benefits and health risks","volume":"87","author":"Pastuszek O","year":"2026","unstructured":"Pastuszek O, Borowski K, Radziwon M, et al.. GLP-1 receptor agonists: a new hope in the global fight against obesity: benefits and health risks. J Educ Health Sport. 2026, 87:67433. 10.12775\/JEHS.2026.87.67433","journal-title":"J Educ Health Sport"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/ije\/2876156","article-title":"Unveiling tirzepatide's therapeutic spectrum: a dual GIP\/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health","volume":"2025","author":"Ghaleb J","year":"2025","unstructured":"Ghaleb J, Khouzami KK, Nassif N, et al.. Unveiling tirzepatide's therapeutic spectrum: a dual GIP\/GLP-1 agonist targeting metabolic, neurological, and cardiovascular health. Int J Endocrinol. 2025, 2025:2876156. 10.1155\/ije\/2876156","journal-title":"Int J Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5498\/wjp.v11.i10.696","article-title":"Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: state-of-the-art and future perspectives","volume":"11","author":"Chang SC","year":"2021","unstructured":"Chang SC, Goh KK, Lu ML. Metabolic disturbances associated with antipsychotic drug treatment in patients with schizophrenia: state-of-the-art and future perspectives. World J Psychiatry. 2021, 11:696-710. 10.5498\/wjp.v11.i10.696","journal-title":"World J Psychiatry"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2396396","article-title":"Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review","volume":"23","author":"Solmi M","year":"2024","unstructured":"Solmi M, Miola A, Capone F, et al.. Risk factors, prevention and treatment of weight gain associated with the use of antidepressants and antipsychotics: a state-of-the-art clinical review. Expert Opin Drug Saf. 2024, 23:1249-69. 10.1080\/14740338.2024.2396396","journal-title":"Expert Opin Drug Saf"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.623681","article-title":"The burden of antipsychotic-induced weight gain and metabolic syndrome in children","volume":"12","author":"Libowitz MR","year":"2021","unstructured":"Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry. 2021, 12:623681. 10.3389\/fpsyt.2021.623681","journal-title":"Front Psychiatry"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062741","article-title":"Impact of glucagon-like peptide-1 receptor agonists on mental illness: evidence from a Mendelian randomization study","volume":"26","author":"Xiang L","year":"2025","unstructured":"Xiang L, Peng Y. Impact of glucagon-like peptide-1 receptor agonists on mental illness: evidence from a Mendelian randomization study. Int J Mol Sci. 2025, 26:2741. 10.3390\/ijms26062741","journal-title":"Int J Mol Sci"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12795","article-title":"Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial","volume":"19","author":"Ish\u00f8y PL","year":"2017","unstructured":"Ish\u00f8y PL, Knop FK, Broberg BV, et al.. Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017, 19:162-71. 10.1111\/dom.12795","journal-title":"Diabetes Obes Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/acps.13734","article-title":"Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis","volume":"150","author":"Bak M","year":"2024","unstructured":"Bak M, Campforts B, Domen P, van Amelsvoort T, Drukker M. Glucagon-like peptide agonists for weight management in antipsychotic-induced weight gain: a systematic review and meta-analysis. Acta Psychiatr Scand. 2024, 150:516-29. 10.1111\/acps.13734","journal-title":"Acta Psychiatr Scand"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis A","year":"2024","unstructured":"Guirguis A, Chiappini S, Papanti PG, et al.. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024, 82:82-91. 10.1016\/j.euroneuro.2024.02.003","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-022-03758-w","article-title":"Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder","volume":"22","author":"Doane MJ","year":"2022","unstructured":"Doane MJ, Bessonova L, Friedler HS, et al.. Weight gain and comorbidities associated with oral second-generation antipsychotics: analysis of real-world data for patients with schizophrenia or bipolar I disorder. BMC Psychiatry. 2022, 22:114. 10.1186\/s12888-022-03758-w","journal-title":"BMC Psychiatry"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2023.532","article-title":"Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST)","volume":"9","author":"Siskind D","year":"2023","unstructured":"Siskind D, Baker A, Russell A, et al.. Effects of semaglutide on body weight in clozapine-treated people with schizophrenia and obesity: study protocol for a placebo-controlled, randomised multicentre trial (COaST). BJPsych Open. 2023, 9:e136. 10.1192\/bjo.2023.532","journal-title":"BJPsych Open"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard FS","year":"2020","unstructured":"Willard FS, Douros JD, Gabe MB, et al.. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020, 5:140532. 10.1172\/jci.insight.140532","journal-title":"JCI Insight"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/jobe\/3442754","article-title":"Weight loss efficacy of tirzepatide compared to placebo or GLP-1 receptor agonists in adults with obesity or overweight: a meta-analysis of randomized controlled trials with \u2265 20\u2009weeks treatment duration","volume":"2025","author":"Khawaji A","year":"2025","unstructured":"Khawaji A, Jaly AA, Bakri HA, Ravi R, Hattan A, Khawaji A, Najmi W. Weight loss efficacy of tirzepatide compared to placebo or GLP-1 receptor agonists in adults with obesity or overweight: a meta-analysis of randomized controlled trials with \u2265 20\u2009weeks treatment duration. J Obes. 2025, 2025:3442754. 10.1155\/jobe\/3442754","journal-title":"J Obes"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi OS","year":"2023","unstructured":"Alkhezi OS, Alahmed AA, Alfayez OM, Alzuman OA, Almutairi AR, Almohammed OA. Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials. Obes Rev. 2023, 24:e13543. 10.1111\/obr.13543","journal-title":"Obes Rev"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16294","article-title":"Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice","volume":"27","author":"Zhang A","year":"2025","unstructured":"Zhang A, Liu Q, Xiong Y, et al.. Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice. Diabetes Obes Metab. 2025, 27:2844-56. 10.1111\/dom.16294","journal-title":"Diabetes Obes Metab"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2025.174012","article-title":"Systematic review and meta-analysis of weight gain and metabolic changes in children and adolescents using second-generation antipsychotics","volume":"251","author":"Collares SF","year":"2025","unstructured":"Collares SF, de \u00c1vila J\u00fanior AM, Martins TC, Rezende VH, Romano-Silva MA, Santos RM, de Miranda DM. Systematic review and meta-analysis of weight gain and metabolic changes in children and adolescents using second-generation antipsychotics. Pharmacol Biochem Behav. 2025, 251:174012. 10.1016\/j.pbb.2025.174012","journal-title":"Pharmacol Biochem Behav"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1153648","article-title":"Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis","volume":"14","author":"Khaity A","year":"2023","unstructured":"Khaity A, Mostafa Al-Dardery N, Albakri K, et al.. Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis. Front Psychiatry. 2023, 14:1153648. 10.3389\/fpsyt.2023.1153648","journal-title":"Front Psychiatry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.12775\/JEHS.2025.78.57712","article-title":"Glucagon-like peptide 1 receptor agonists in obesity treatment: a literature review","volume":"78","author":"Jentkiewicz A","year":"2025","unstructured":"Jentkiewicz A, Haj Obeid E, Ulrych J, et al.. Glucagon-like peptide 1 receptor agonists in obesity treatment: a literature review. J Educ Health Sport. 2025, 78:57712. 10.12775\/JEHS.2025.78.57712","journal-title":"J Educ Health Sport"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.12775\/JEHS.2025.79.58305","article-title":"The worldwide problem of obesity: comparison of the effectiveness of pharmacological treatment with semaglutide and tirzepatide in reducing body weight","volume":"79","author":"Garbino K","year":"2025","unstructured":"Garbino K, Brudniak K, Czyczerska M, et al.. The worldwide problem of obesity: comparison of the effectiveness of pharmacological treatment with semaglutide and tirzepatide in reducing body weight. J Educ Health Sport. 2025, 79:58305. 10.12775\/JEHS.2025.79.58305","journal-title":"J Educ Health Sport"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-018-0053-9","article-title":"Risk of weight gain for specific antipsychotic drugs: a meta-analysis","volume":"4","author":"Spertus J","year":"2018","unstructured":"Spertus J, Horvitz-Lennon M, Abing H, Normand SL. Risk of weight gain for specific antipsychotic drugs: a meta-analysis. NPJ Schizophr. 2018, 4:12. 10.1038\/s41537-018-0053-9","journal-title":"NPJ Schizophr"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi R","year":"2025","unstructured":"De Giorgi R, Ghenciulescu A, Dziwisz O, et al.. An analysis on the role of glucagon-like peptide 1 receptor agonists in cognitive and mental health disorders. Nat Ment Health. 2025, 3:354-73. 10.1038\/s44220-025-00390-x","journal-title":"Nat Ment Health"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius E","year":"2024","unstructured":"Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024, 14:24433. 10.1038\/s41598-024-75965-2","journal-title":"Sci Rep"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.20230922","article-title":"Psychotropic drug-related weight gain and its treatment","volume":"181","author":"McIntyre RS","year":"2024","unstructured":"McIntyre RS, Kwan AT, Rosenblat JD, Teopiz KM, Mansur RB. Psychotropic drug-related weight gain and its treatment. Am J Psychiatry. 2024, 181:26-38. 10.1176\/appi.ajp.20230922","journal-title":"Am J Psychiatry"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/20451253231165169","article-title":"Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin: a case series","volume":"13","author":"Prasad F","year":"2023","unstructured":"Prasad F, De R, Korann V, et al.. Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin: a case series. Ther Adv Psychopharmacol. 2023, 13:20451253231165169. 10.1177\/20451253231165169","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0285197","article-title":"Weight loss efficiency and safety of tirzepatide: a systematic review","volume":"18","author":"Lin F","year":"2023","unstructured":"Lin F, Yu B, Ling B, et al.. Weight loss efficiency and safety of tirzepatide: a systematic review. PLoS One. 2023, 18:e0285197. 10.1371\/journal.pone.0285197","journal-title":"PLoS One"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114227","article-title":"Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine","volume":"306","author":"Klemettil\u00e4 JP","year":"2021","unstructured":"Klemettil\u00e4 JP, Solismaa A, Sepp\u00e4l\u00e4 N, H\u00e4m\u00e4l\u00e4inen M, Moilanen E, Leinonen E, Kampman O. Glucagon-like peptide-1 serum levels are associated with weight gain in patients treated with clozapine. Psychiatry Res. 2021, 306:114227. 10.1016\/j.psychres.2021.114227","journal-title":"Psychiatry Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy M","year":"2024","unstructured":"Tobaiqy M, Elkout H. Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database. Int J Clin Pharm. 2024, 46:488-95. 10.1007\/s11096-023-01694-7","journal-title":"Int J Clin Pharm"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.1220","article-title":"Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial","volume":"74","author":"Larsen JR","year":"2017","unstructured":"Larsen JR, Vedtofte L, Jakobsen MS, et al.. Effect of liraglutide treatment on prediabetes and overweight or obesity in clozapine- or olanzapine-treated patients with schizophrenia spectrum disorder: a randomized clinical trial. JAMA Psychiatry. 2017, 74:719-28. 10.1001\/jamapsychiatry.2017.1220","journal-title":"JAMA Psychiatry"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14334","article-title":"The use of liraglutide 3.0\u00a0mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial","volume":"23","author":"Whicher CA","year":"2021","unstructured":"Whicher CA, Price HC, Phiri P, et al.. The use of liraglutide 3.0\u00a0mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: results of a pilot randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2021, 23:1262-71. 10.1111\/dom.14334","journal-title":"Diabetes Obes Metab"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12982","article-title":"One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients","volume":"139","author":"Svensson CK","year":"2019","unstructured":"Svensson CK, Larsen JR, Vedtofte L, et al.. One-year follow-up on liraglutide treatment for prediabetes and overweight\/obesity in clozapine- or olanzapine-treated patients. Acta Psychiatr Scand. 2019, 139:26-36. 10.1111\/acps.12982","journal-title":"Acta Psychiatr Scand"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.25cr03952","article-title":"GLP-1 receptor agonists for clozapine-induced weight gain: a case report with the dual GLP-1\/GIP agonist tirzepatide","volume":"27","author":"Lim C","year":"2025","unstructured":"Lim C, Maclaurin S, Donovan AL, Foo CY, Freudenreich O. GLP-1 receptor agonists for clozapine-induced weight gain: a case report with the dual GLP-1\/GIP agonist tirzepatide. Prim Care Companion CNS Disord. 2025, 27:25cr03952. 10.4088\/PCC.25cr03952","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/510298-glp-1-glucagon-like-peptide-1-and-gip-glucose-dependent-insulinotropic-polypeptideglp-1-receptor-agonists-for-antipsychotic-induced-weight-gain-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:05:40Z","timestamp":1786568740000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/510298-glp-1-glucagon-like-peptide-1-and-gip-glucose-dependent-insulinotropic-polypeptideglp-1-receptor-agonists-for-antipsychotic-induced-weight-gain-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.114435","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}